News in brief: PBS listing extended for anti-epilepsy drug; Pfizer COVID-19 vaccine side effects mild in neurologically disabled children; Neuroscience researcher aims for Eureka prize

PBS listing extended for epilepsy drug Lacosamide’s (Vimpat) PBS listing has been extended to cover treatment of idiopathic generalised epilepsy with primary generalised tonic-clonic seizures (PGTCS). From 1 September, neurologists and paediatricians can prescribe government-funded, add-on lacosamide to eligible patients with uncontrolled seizures — dropping the price of a 56-tablet packet from $154.66 to $41.30 ...

Already a member?

Login to keep reading.

© 2021 the limbic